By Jodi Avergun (October 29, 2018, 3:44 PM EDT) -- The opioid package President Donald Trump signed last week garnered much attention. While it is largely directed at treatment and prevention, it contains several momentous provisions for those companies that manufacture, distribute or dispense opioid medications. This article discusses a few of the more important provisions that are anticipated to affect the pharmaceutical industry in its interactions with the U.S. Drug Enforcement Administration. In short, the act imposes new requirements on wholesale distributors related to handling of controlled substances and increases penalties for failing to comply with the act and, interestingly, imposes quite significant analytical and reporting hurdles on the Drug Enforcement Administration and, to a lesser extent, the U.S. Department of Health and Human Services....